Yashmin Choudhury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yashmin Choudhury has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Moumita Nath
Department of Biotechnology, Assam University, Silchar, 788011, Assam, India
9 shared publicationsKasturi Bhattacharjee
Department of Biotechnology, Assam University, Silchar, 788011, Assam, India
7 shared publicationsSambuddha Das
Assam Univ, Dept Biotechnol, Silchar 788011, India
6 shared publicationsSankar Kumar Ghosh
Assam Univ, Dept Biotechnol, Silchar 788011, India
6 shared publicationsAditi Bhowmik
Assam Univ, Dept Biotechnol, Silchar 788011, India
5 shared publicationsBarnali Sinha
5 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Elsevier in SSRN Electronic Journal
Alleviation of high fat diet-induced obesity in mice by Samia ricini pupae protein
Obesity is a multifactorial metabolic disorder associated with aberrant lipid metabolism, dyslipidemia, oxidative stress and chronic low-grade inflammation. Edible insects are an underexplored source of nutrition and functional foods. The pupae of the eri silkworm, Samia ricini, have been traditionally consumed by several tribes of North-East India for their nutritive and therapeutic properties. We evaluated the potential of protein extracted from Samia ricini pupae (PESRP) to alleviate obesity induced in mice by high-fat diet (HFD). PESRP did not induce acute toxicity and had an LD50 greater than 1000 mg/ kg body weight (bw). It significantly decreased body weight, adipocyte hypertrophy, and normalized serum lipid profile of HFD-fed obese mice in a dose-dependent manner, the 100 mg/kg bw dose producing effects similar to the standard anti-obesity drug, orlistat (20 mg/kg bw). It also ameliorated hepatic steatosis and normalized the levels of liver function markers in the obese mice. Mechanistically, PESRP activated AMPK signaling by increasing the ratio of pAMPK (Thr 172)/AMPK and pACC (Ser-79)/ACC and downregulating the expression of lipogenic enzymes FASN and HMGCR in both liver and epididymal white adipose tissue (eWAT). Moreover PESRP reduced obesity associated inflammation in both liver and eWAT by reducing expression of TNF-α and NF-ķβ, reduced oxidative stress and restored reduced glutathione levels in these tissues. Molecular docking indicate that peptides of PESRP potentially activate AMPKα by binding to the human AMPK Allosteric Drug and Metabolite (ADaM) pocket This study indicates PESRP holds promise as a novel edible insect-derived nutraceutical for obesity management.
- 16 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAlleviation of high fat diet-induced obesity in mice by Samia ricini pupae protein
Obesity is a multifactorial metabolic disorder associated with aberrant lipid metabolism, dyslipidemia, oxidative stress and chronic low-grade inflammation. Edible insects are an underexplored source of nutrition and functional foods. The pupae of the eri silkworm, Samia ricini, have been traditionally consumed by several tribes of North-East India for their nutritive and therapeutic properties. We evaluated the potential of protein extracted from Samia ricini pupae (PESRP) to alleviate obesity induced in mice by high-fat diet (HFD). PESRP did not induce acute toxicity and had an LD50 greater than 1000 mg/ kg body weight (bw). It significantly decreased body weight, adipocyte hypertrophy, and normalized serum lipid profile of HFD-fed obese mice in a dose-dependent manner, the 100 mg/kg bw dose producing effects similar to the standard anti-obesity drug, orlistat (20 mg/kg bw). It also ameliorated hepatic steatosis and normalized the levels of liver function markers in the obese mice. Mechanistically, PESRP activated AMPK signaling by increasing the ratio of pAMPK (Thr 172)/AMPK and pACC (Ser-79)/ACC and downregulating the expression of lipogenic enzymes FASN and HMGCR in both liver and epididymal white adipose tissue (eWAT). Moreover PESRP reduced obesity associated inflammation in both liver and eWAT by reducing expression of TNF-α and NF-ķβ, reduced oxidative stress and restored reduced glutathione levels in these tissues. Molecular docking indicate that peptides of PESRP potentially activate AMPKα by binding to the human AMPK Allosteric Drug and Metabolite (ADaM) pocket This study indicates PESRP holds promise as a novel edible insect-derived nutraceutical for obesity management.
- Open Access
- 14 June 2026
- Published by Elsevier in SSRN Electronic Journal
Alleviation of high fat diet-induced obesity in mice by Samia ricini pupae protein
Obesity is a multifactorial metabolic disorder associated with aberrant lipid metabolism, dyslipidemia, oxidative stress and chronic low-grade inflammation. Edible insects are an underexplored source of nutrition and functional foods. The pupae of the eri silkworm, Samia ricini, have been traditionally consumed by several tribes of North-East India for their nutritive and therapeutic properties. We evaluated the potential of protein extracted from Samia ricini pupae (PESRP) to alleviate obesity induced in mice by high-fat diet (HFD). PESRP did not induce acute toxicity and was established to have an LD50 greater than 1000 mg/ kg body weight (bw). PESRP significantly decreased body weight and adipocyte hypertrophy, and normalized serum lipid profile of HFD-fed obese mice in a dose-dependent manner, with the 100 mg/kg bw dose producing effects similar to the standard anti-obesity drug, orlistat (20 mg/kg bw). It also ameliorated hepatic steatosis and normalized the levels of liver function markers in HFD fed obese mice. Mechanistically, PESRP activated AMPK signaling by increasing the ratio of pAMPK (Thr 172)/AMPK and pACC (Ser-79)/ACC and downregulating the expression of lipogenic enzymes FASN and HMGCR in both liver and epididymal white adipose tissue (eWAT). Moreover PESRP reduced obesity associated inflammation in both liver and eWAT by reducing expression of TNF-α and NF-ķβ, reduced oxidative stress and restored reduced glutathione levels in these tissues. Altogether, this study suggests that PESRP potentially attenuates obesity induced by HFD and holds promise as a novel edible insect-derived nutraceutical for obesity management.
- 14 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAlleviation of high fat diet-induced obesity in mice by Samia ricini pupae protein
Obesity is a multifactorial metabolic disorder associated with aberrant lipid metabolism, dyslipidemia, oxidative stress and chronic low-grade inflammation. Edible insects are an underexplored source of nutrition and functional foods. The pupae of the eri silkworm, Samia ricini, have been traditionally consumed by several tribes of North-East India for their nutritive and therapeutic properties. We evaluated the potential of protein extracted from Samia ricini pupae (PESRP) to alleviate obesity induced in mice by high-fat diet (HFD). PESRP did not induce acute toxicity and was established to have an LD50 greater than 1000 mg/ kg body weight (bw). PESRP significantly decreased body weight and adipocyte hypertrophy, and normalized serum lipid profile of HFD-fed obese mice in a dose-dependent manner, with the 100 mg/kg bw dose producing effects similar to the standard anti-obesity drug, orlistat (20 mg/kg bw). It also ameliorated hepatic steatosis and normalized the levels of liver function markers in HFD fed obese mice. Mechanistically, PESRP activated AMPK signaling by increasing the ratio of pAMPK (Thr 172)/AMPK and pACC (Ser-79)/ACC and downregulating the expression of lipogenic enzymes FASN and HMGCR in both liver and epididymal white adipose tissue (eWAT). Moreover PESRP reduced obesity associated inflammation in both liver and eWAT by reducing expression of TNF-α and NF-ķβ, reduced oxidative stress and restored reduced glutathione levels in these tissues. Altogether, this study suggests that PESRP potentially attenuates obesity induced by HFD and holds promise as a novel edible insect-derived nutraceutical for obesity management.
- Open Access
- 23 February 2026
- Published by Elsevier in SSRN Electronic Journal
An in silico approach to identifying the potential anti-diabetic, anti-hypertensive and anti-cancer bioactivities of peptides derived from the edible pupae of the eri silkworm, Samia ricini
As emerging sustainable food sources, edible insects are rich in proteins with considerable therapeutic potential. The fate of edible insect proteins during human gastrointestinal (GI) digestion and the nature of released peptides under physiological digestive conditions remain poorly characterized. Conventional bioactive peptide discovery relies on enzymatic hydrolysis followed by extensive in vitro and in vivo experimental validation, which is time and resource intensive. Consequently, in silico approaches and molecular docking study are increasingly employed in bioactive peptide discovery and structure-function relationships directly from peptide sequences. In this study, high-confidence with an average local confidence (ALC) ≥95%, de novo peptide sequences of Samia ricini pupae protein were filtered out for downstream in silico analysis. Bioactive potential of the sequences was predicted using PepRank score, while antioxidant potential, toxicity, and physicochemical properties were evaluated using AnOxPePred, ToxinPred, and ProtParam, respectively. Peptides were further subjected to simulated gastrointestinal (GI) digestion to mimic the fate of peptides in the human GI digestive system, which were subsequently screened in the BIOPEP-UWMTM database to identify previously reported and potentially novel bioactive peptides. Simulated GI digestion released multifunctional bioactive peptides with predicted antioxidant, antihypertensive, antidiabetic, anti-obesity, and anticancer activities. Molecular docking analysis of selected putative novel peptides against key therapeutic targets, including Dipeptidyl peptidase-4 (3W2T), Angiotensin-converting enzyme (1R4L), and Cathepsin L (7Z3T) revealed that the peptides SGL, YR and VSW respectively bind within the active sites of the targets, acting as potential inhibitors. Overall, this study identifies S. ricini pupae as a promising source of bioactive peptides.
- 23 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAn in silico approach to identifying the potential anti-diabetic, anti-hypertensive and anti-cancer bioactivities of peptides derived from the edible pupae of the eri silkworm, Samia ricini
As emerging sustainable food sources, edible insects are rich in proteins with considerable therapeutic potential. The fate of edible insect proteins during human gastrointestinal (GI) digestion and the nature of released peptides under physiological digestive conditions remain poorly characterized. Conventional bioactive peptide discovery relies on enzymatic hydrolysis followed by extensive in vitro and in vivo experimental validation, which is time and resource intensive. Consequently, in silico approaches and molecular docking study are increasingly employed in bioactive peptide discovery and structure-function relationships directly from peptide sequences. In this study, high-confidence with an average local confidence (ALC) ≥95%, de novo peptide sequences of Samia ricini pupae protein were filtered out for downstream in silico analysis. Bioactive potential of the sequences was predicted using PepRank score, while antioxidant potential, toxicity, and physicochemical properties were evaluated using AnOxPePred, ToxinPred, and ProtParam, respectively. Peptides were further subjected to simulated gastrointestinal (GI) digestion to mimic the fate of peptides in the human GI digestive system, which were subsequently screened in the BIOPEP-UWMTM database to identify previously reported and potentially novel bioactive peptides. Simulated GI digestion released multifunctional bioactive peptides with predicted antioxidant, antihypertensive, antidiabetic, anti-obesity, and anticancer activities. Molecular docking analysis of selected putative novel peptides against key therapeutic targets, including Dipeptidyl peptidase-4 (3W2T), Angiotensin-converting enzyme (1R4L), and Cathepsin L (7Z3T) revealed that the peptides SGL, YR and VSW respectively bind within the active sites of the targets, acting as potential inhibitors. Overall, this study identifies S. ricini pupae as a promising source of bioactive peptides.
- Open Access
- 6 January 2025
- Published by Oxford University Press (OUP) in International Journal of Food Science and Technology
- Vol. 60 (1)
Antioxidant, anti-inflammatory, α-amylase inhibitory, and thrombolytic properties of proteins derived from the edible pupae of the eri silkworm (Samia ricini): a potential source of functional foods
Samia ricini is a silkmoth cultivated for the production of eri silk. Its edible pupae are a component of the traditional diet of various communities. The present study aimed to evaluate the beneficial properties of protein extract of S. ricini pupae (PESRP) in vitro and in vivo. PESRP showed significant free radical scavenging activity of 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH) (IC50 86.9 ± 2.5 μg/ml) and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) (IC50 372.5 ± 4.2 μg/ml) radicals; lower Fe3+ and Cu2+ chelating activities than ascorbic acid (AA) but higher than butylated hydroxytoluene (BHT) assessed through ferric ion reducing antioxidant power (FRAP) and total antioxidant capacity assays; significant in vitro anti-inflammatory efficacy assessed by egg albumin denaturation inhibition and lipoxygenase (LOXs) inhibition assays; and significant alpha-amylase inhibition and thrombolytic efficacies in vitro. PESRP also significantly reduced inflammation and oxidative stress in mouse paw edema induced by carrageenan, in vivo. Administration of PESRP did not increase serum IgE levels in comparison to control mice. Moreover, peptide sequencing by LC–MS/MS revealed the presence of a high percentage of amino acids with free radical scavenging properties in PESRP. Taken together, this study indicates that the proteins extracted from the edible pupae of S. ricini have health benefits as natural antioxidant and anti-inflammatory agents, with potential applications in diabetes control and blood clot lysis.
- 6 January 2025
- Published by Oxford University Press (OUP) in International Journal of Food Science and Technology
- Vol. 60 (1)
Open AccessAntioxidant, anti-inflammatory, α-amylase inhibitory, and thrombolytic properties of proteins derived from the edible pupae of the eri silkworm (Samia ricini): a potential source of functional foods
Samia ricini is a silkmoth cultivated for the production of eri silk. Its edible pupae are a component of the traditional diet of various communities. The present study aimed to evaluate the beneficial properties of protein extract of S. ricini pupae (PESRP) in vitro and in vivo. PESRP showed significant free radical scavenging activity of 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH) (IC50 86.9 ± 2.5 μg/ml) and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) (IC50 372.5 ± 4.2 μg/ml) radicals; lower Fe3+ and Cu2+ chelating activities than ascorbic acid (AA) but higher than butylated hydroxytoluene (BHT) assessed through ferric ion reducing antioxidant power (FRAP) and total antioxidant capacity assays; significant in vitro anti-inflammatory efficacy assessed by egg albumin denaturation inhibition and lipoxygenase (LOXs) inhibition assays; and significant alpha-amylase inhibition and thrombolytic efficacies in vitro. PESRP also significantly reduced inflammation and oxidative stress in mouse paw edema induced by carrageenan, in vivo. Administration of PESRP did not increase serum IgE levels in comparison to control mice. Moreover, peptide sequencing by LC–MS/MS revealed the presence of a high percentage of amino acids with free radical scavenging properties in PESRP. Taken together, this study indicates that the proteins extracted from the edible pupae of S. ricini have health benefits as natural antioxidant and anti-inflammatory agents, with potential applications in diabetes control and blood clot lysis.
- Open Access
- 1 January 2025
- Published by CSIR-National Institute of Science Communication and Policy Research (NIScPR) in Indian Journal of Biochemistry and Biophysics
- Vol. 62 (4) , 222-236
A review on repurposing anti-diabetic drugs for the amelioration of betel-nut induced carcinogenesis
Betel-nut (BN) chewing is a socially ingrained practice in several populations worldwide, and is the fourth most addictive habit with several detrimental impacts on health. BN is classified as a class I carcinogen, and its use is associated with the development and progression of cancer through various mechanisms such as the production of nitrosamines, increased oxidative stress, activation of the PI3K/Akt/mTOR pathway, inhibition of tumor suppressors and the dysregulation of cellular energetics, apoptosis and autophagy. Several of these mechanisms overlap with the pathogenesis of diabetes mellitus, making anti-diabetic drugs good candidates for drug repurposing as anti-cancer agents. While a large body of experimental evidence has established the effectiveness of the anti-diabetic drug, metformin, as an anti-cancer agent, clinical trials have largely failed to produce promising results. Our own work as well as that of other workers have also indicated the anti-cancer potential of the dipeptidyl peptidase-4 inhibitor, vildagliptin, though the thiazolidinedione, pioglitazone, was found to have more limited effectiveness and also produced ambiguous results in clinical studies. This review focuses on the mechanisms of BN-induced carcinogenesis and the potential of exploring common anti-diabetic drugs for its amelioration.
- 1 January 2025
- Published by CSIR-National Institute of Science Communication and Policy Research (NIScPR) in Indian Journal of Biochemistry and Biophysics
- Vol. 62 (4) , 222-236
Open AccessA review on repurposing anti-diabetic drugs for the amelioration of betel-nut induced carcinogenesis
Betel-nut (BN) chewing is a socially ingrained practice in several populations worldwide, and is the fourth most addictive habit with several detrimental impacts on health. BN is classified as a class I carcinogen, and its use is associated with the development and progression of cancer through various mechanisms such as the production of nitrosamines, increased oxidative stress, activation of the PI3K/Akt/mTOR pathway, inhibition of tumor suppressors and the dysregulation of cellular energetics, apoptosis and autophagy. Several of these mechanisms overlap with the pathogenesis of diabetes mellitus, making anti-diabetic drugs good candidates for drug repurposing as anti-cancer agents. While a large body of experimental evidence has established the effectiveness of the anti-diabetic drug, metformin, as an anti-cancer agent, clinical trials have largely failed to produce promising results. Our own work as well as that of other workers have also indicated the anti-cancer potential of the dipeptidyl peptidase-4 inhibitor, vildagliptin, though the thiazolidinedione, pioglitazone, was found to have more limited effectiveness and also produced ambiguous results in clinical studies. This review focuses on the mechanisms of BN-induced carcinogenesis and the potential of exploring common anti-diabetic drugs for its amelioration.
- Open Access
- 1 November 2024
- Published by Manuscript Technomedia LLP in Pharmacognosy Journal
- Vol. 16 (5) , 1021-1028
Berberine Mitigates Betel-Nut Induced Hepatocarcinogenesis, Enhances Chemosensitivity to Cisplatin and Reduces Cisplatin- Induced Nephrotoxicity in Mice Exposed to an Aqueous Extract of Betel Nut
Background: There is a considerable correlation between the use of betel-nut (BN) as a chewing substance and the development of various malignancies. Objective: The bioactive phytocompound berberine was tested as monotherapy or in combination with cisplatin to reduce BN-induced carcinogenesis in mice. We also examined how berberine affected cisplatin-induced toxicity. Methods: Swiss Albino mice were exposed to aqueous extract of betel-nut (AEBN) at a dose of 2 mg ml-1 in drinking water, for 16 weeks. Following this, the mice were given a combination of AEBN and berberine (10 mg kg-1) for 8 weeks. Control mice were given drinking water without AEBN for 24 weeks. For the combination treatment, mice that had been exposed to AEBN (2 mg ml-1) for 16 weeks were given AEBN+sodiumchloride+cisplatin (5 mg kg-1) +berberine (10 mg kg-1) for 2 weeks. Histopathology, oxidative stress, proliferation, apoptosis, oncogenic and tumor suppressor proteins, hepatotoxicity, and nephrotoxicity were assessed in tissues retrieved at treatment endpoints. Results: Berberine monotherapy reduced tissue dysplasia, liver nodulation, oxidative stress, proliferation (Ki-67 and Cyclin D1) markers, Akt/mTOR signaling, and pP53 (Ser-15) levels and apoptosis in AEBN-treated mice to levels comparable to cisplatin alone. Berberine with cisplatin decreased nephrotoxicity, fur shedding, and cancer phenotype more than cisplatin alone. Conclusion: The study results imparted a new therapeutic approach in developing more effective and less harmful cancer treatments.
- 1 November 2024
- Published by Manuscript Technomedia LLP in Pharmacognosy Journal
- Vol. 16 (5) , 1021-1028
Open AccessBerberine Mitigates Betel-Nut Induced Hepatocarcinogenesis, Enhances Chemosensitivity to Cisplatin and Reduces Cisplatin- Induced Nephrotoxicity in Mice Exposed to an Aqueous Extract of Betel Nut
Background: There is a considerable correlation between the use of betel-nut (BN) as a chewing substance and the development of various malignancies. Objective: The bioactive phytocompound berberine was tested as monotherapy or in combination with cisplatin to reduce BN-induced carcinogenesis in mice. We also examined how berberine affected cisplatin-induced toxicity. Methods: Swiss Albino mice were exposed to aqueous extract of betel-nut (AEBN) at a dose of 2 mg ml-1 in drinking water, for 16 weeks. Following this, the mice were given a combination of AEBN and berberine (10 mg kg-1) for 8 weeks. Control mice were given drinking water without AEBN for 24 weeks. For the combination treatment, mice that had been exposed to AEBN (2 mg ml-1) for 16 weeks were given AEBN+sodiumchloride+cisplatin (5 mg kg-1) +berberine (10 mg kg-1) for 2 weeks. Histopathology, oxidative stress, proliferation, apoptosis, oncogenic and tumor suppressor proteins, hepatotoxicity, and nephrotoxicity were assessed in tissues retrieved at treatment endpoints. Results: Berberine monotherapy reduced tissue dysplasia, liver nodulation, oxidative stress, proliferation (Ki-67 and Cyclin D1) markers, Akt/mTOR signaling, and pP53 (Ser-15) levels and apoptosis in AEBN-treated mice to levels comparable to cisplatin alone. Berberine with cisplatin decreased nephrotoxicity, fur shedding, and cancer phenotype more than cisplatin alone. Conclusion: The study results imparted a new therapeutic approach in developing more effective and less harmful cancer treatments.
- Open Access
- 2 February 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1345281
Revisiting edible insects as sources of therapeutics and drug delivery systems for cancer therapy
Cancer has been medicine’s most formidable foe for long, and the rising incidence of the disease globally has made effective cancer therapy a significant challenge. Drug discovery is targeted at identifying efficacious compounds with minimal side effects and developments in nanotechnology and immunotherapy have shown promise in the fight against this complicated illness. Since ancient times, insects and insect-derived products have played a significant role in traditional medicine across several communities worldwide. The aim of this study was to inspect the traditional use of edible insects in various cultures and to explore their modern use in cancer therapy. Edible insects are sources of nutrients and a variety of beneficial substances with anticancer and immunomodulatory potential. Recently, insect derived bioactive-components have also been used as nanoparticles either in combination with chemotherapeutics or as a nano-cargo for the enhanced delivery of chemotherapeutic drugs due to their high biocompatibility, low bio-toxicity, and their antioxidant and anticancer effects. The crude extracts of different edible insects and their active components such as sericin, cecropin, solenopsin, melittin, antimicrobial peptides and fibroin produce anti-cancer and immunomodulatory effects by various mechanisms which have been discussed in this review.
- 2 February 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1345281
Open AccessRevisiting edible insects as sources of therapeutics and drug delivery systems for cancer therapy
Cancer has been medicine’s most formidable foe for long, and the rising incidence of the disease globally has made effective cancer therapy a significant challenge. Drug discovery is targeted at identifying efficacious compounds with minimal side effects and developments in nanotechnology and immunotherapy have shown promise in the fight against this complicated illness. Since ancient times, insects and insect-derived products have played a significant role in traditional medicine across several communities worldwide. The aim of this study was to inspect the traditional use of edible insects in various cultures and to explore their modern use in cancer therapy. Edible insects are sources of nutrients and a variety of beneficial substances with anticancer and immunomodulatory potential. Recently, insect derived bioactive-components have also been used as nanoparticles either in combination with chemotherapeutics or as a nano-cargo for the enhanced delivery of chemotherapeutic drugs due to their high biocompatibility, low bio-toxicity, and their antioxidant and anticancer effects. The crude extracts of different edible insects and their active components such as sericin, cecropin, solenopsin, melittin, antimicrobial peptides and fibroin produce anti-cancer and immunomodulatory effects by various mechanisms which have been discussed in this review.
- 31 May 2023
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 75 (7) , 1579-1599
Protective Effects of Pelargonidin against DMBA-Induced Mammary Tumorigenesis in BALB/c Mice through Reduced Oxidative Stress and Lipid Anomalies
Among luminal types of breast cancers, ER + breast cancer is the most frequently diagnosed cancer globally. ER + breast cancer is commonly treated with SERM drugs that block ER to prevent ER-mediated cancerous growth. Our previous computational screening found pelargonidin (PG) can inhibit ER-signaling with potent bioactivity and satisfactory toxicological features. The present study explored the anti-tumoral prospect of PG against DMBA-induced ER + murine mammary carcinogenesis. The female BALB/c mice were divided into control (A) and DMBA-exposed groups. Following tumor appearance, the DMBA-exposed group was divided into five groups: tumor control, PG-treated (Groups P25, P50, and P100), and tamoxifen-treated (TAM). The results indicated that PG-treatment dose-dependently reduced the mean tumor volume, reinstated body weight loss, and enhanced the percentage survival of tumor-bearing mice. In addition, we recorded a significant reduction in LPO, total cholesterol, and triglycerides and a surge in the activity of antioxidases and phase II detoxifying enzymes in PG-treated animals. PG also dose-dependently increased the serum level of unbound estradiol, an indicator of competitive ER binding by an ER agonist/antagonist. These data suggest that pelargonidin has potent anticancer potential against the animal model of ER + breast cancer that matches the efficiency of tamoxifen with conceivably fewer side effects.
- 31 May 2023
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 75 (7) , 1579-1599
Protective Effects of Pelargonidin against DMBA-Induced Mammary Tumorigenesis in BALB/c Mice through Reduced Oxidative Stress and Lipid Anomalies
Among luminal types of breast cancers, ER + breast cancer is the most frequently diagnosed cancer globally. ER + breast cancer is commonly treated with SERM drugs that block ER to prevent ER-mediated cancerous growth. Our previous computational screening found pelargonidin (PG) can inhibit ER-signaling with potent bioactivity and satisfactory toxicological features. The present study explored the anti-tumoral prospect of PG against DMBA-induced ER + murine mammary carcinogenesis. The female BALB/c mice were divided into control (A) and DMBA-exposed groups. Following tumor appearance, the DMBA-exposed group was divided into five groups: tumor control, PG-treated (Groups P25, P50, and P100), and tamoxifen-treated (TAM). The results indicated that PG-treatment dose-dependently reduced the mean tumor volume, reinstated body weight loss, and enhanced the percentage survival of tumor-bearing mice. In addition, we recorded a significant reduction in LPO, total cholesterol, and triglycerides and a surge in the activity of antioxidases and phase II detoxifying enzymes in PG-treated animals. PG also dose-dependently increased the serum level of unbound estradiol, an indicator of competitive ER binding by an ER agonist/antagonist. These data suggest that pelargonidin has potent anticancer potential against the animal model of ER + breast cancer that matches the efficiency of tamoxifen with conceivably fewer side effects.
- Open Access
- 27 April 2023
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 19 (7) , 1967-1974
The antidiabetic drug pioglitazone ameliorates betel-nut-induced carcinogenesis in mice by restoring normal lipid metabolism, reducing oxidative stress, and inducing apoptosis
Context: Oral administration (2 mg mL-1) of aqueous extract of betel nut (AEBN) for 24 weeks induced oncogenic alterations in the liver of female Swiss Albino mice concomitant with aberrant lipid metabolism, overactivation of Akt/mTOR signaling, and loss of apoptosis. Aim: This study was designed to investigate the potential of repurposing the antidiabetic drug pioglitazone for alleviating AEBN-induced carcinogenesis. Methods: Sera of animals were evaluated for lipid profile and free fatty acid levels. Liver tissues were investigated for oxidative stress, histopathology, and expression of proteins involved in lipid metabolism and oncogenesis by western blotting. Apoptosis was determined using TUNEL assay. Results: Coadministration of pioglitazone (10 mg kg-1 b.w) with AEBN for 8 weeks restored normal lipid profile and AMPK/ACC signaling, reduced FASN and HMGCR expressions and oxidative stress, and actively induced Akt/mTOR-mediated apoptosis in the liver. Conclusions: Pioglitazone can effectively alleviate AEBN-induced carcinogenesis in mice.
- 27 April 2023
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 19 (7) , 1967-1974
Open AccessThe antidiabetic drug pioglitazone ameliorates betel-nut-induced carcinogenesis in mice by restoring normal lipid metabolism, reducing oxidative stress, and inducing apoptosis
Context: Oral administration (2 mg mL-1) of aqueous extract of betel nut (AEBN) for 24 weeks induced oncogenic alterations in the liver of female Swiss Albino mice concomitant with aberrant lipid metabolism, overactivation of Akt/mTOR signaling, and loss of apoptosis. Aim: This study was designed to investigate the potential of repurposing the antidiabetic drug pioglitazone for alleviating AEBN-induced carcinogenesis. Methods: Sera of animals were evaluated for lipid profile and free fatty acid levels. Liver tissues were investigated for oxidative stress, histopathology, and expression of proteins involved in lipid metabolism and oncogenesis by western blotting. Apoptosis was determined using TUNEL assay. Results: Coadministration of pioglitazone (10 mg kg-1 b.w) with AEBN for 8 weeks restored normal lipid profile and AMPK/ACC signaling, reduced FASN and HMGCR expressions and oxidative stress, and actively induced Akt/mTOR-mediated apoptosis in the liver. Conclusions: Pioglitazone can effectively alleviate AEBN-induced carcinogenesis in mice.